Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity [5]

Journal of Clinical Oncology

Volumn 25, Issue 13, 2007, Pages 1816-1818

  Loupakis, Fotios ^a   Falcone, Alfredo ^a,b   Masi, Gianluca ^a   Fioravanti, Anna ^b   Kerbel, Robert S ^c   Tacca, Mario Del ^b   Bocci, Guido ^b  

^a General Hospital   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; IMMUNOGLOBULIN; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BIOLOGICAL ACTIVITY; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249100236     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.3051     Document Type: Letter

References (14)

1. Ferrara N, Hillan KJ, Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328-335, 2005
2. Lyseng-Williamson KA, Robinson DM: Bevacizumab: A review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 5:43-60, 2006
3. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
4. Jain RK, Duda DG, Clark JW, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006
5. Shaked Y, Bertolini F, Man S, et al: Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101-111, 2005
6. Bertolini F, Shaked Y, Mancuso P, et al: The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer 6:835-845, 2006
7. Shaked Y, Bocci G, Munoz R, et al: Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 5:551-559, 2005
8. Cristofanilli M, Charnsangavej C, Hortobagyi GN: Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 1:415-426, 2002
9. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
10. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
11. Willett CG, Boucher Y, Duda DG, et al: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136-8139, 2005
12. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
13. Bocci G, Man S, Green SK, et al: Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 64:6616-6625, 2004
14. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006